UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Lititz Record-Express serves Lititz and Manheim as the sole weekly newspaper dedicated to local coverage. Keep up with the extensive events and news in these two towns by subscribing today. Sign up ...